Core Insights - Clearmind Medicine Inc. has successfully completed site initiation at Tel Aviv Sourasky Medical Center for its Phase I/IIa clinical trial of CMND-100, targeting Alcohol Use Disorder (AUD) [1][2] - The trial is multinational and multi-center, assessing safety, tolerability, and pharmacokinetics of CMND-100, while also exploring early efficacy signals [2][3] - CMND-100 utilizes the molecule 5-methoxy-2-aminoindane (MEAI) and has shown promising preclinical results in reducing alcohol cravings, addressing a significant unmet need in AUD treatment [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for under-treated health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents [5] Clinical Trial Details - The Phase I/IIa trial includes prestigious sites such as Yale School of Medicine and Johns Hopkins University, alongside TASMC and Hadassah-University Medical Center [2] - The trial is led by Prof. David Zeltser at TASMC, enhancing Clearmind's clinical network and patient enrollment [2][3]

Core Viewpoint - Clearmind Medicine Inc. is expanding its Phase I/IIa clinical trial for CMND-100, a treatment for Alcohol Use Disorder (AUD), by activating a new site at Johns Hopkins University and enrolling its first participant there, indicating positive momentum in its clinical development program [1][2][3]. Group 1: Clinical Trial Details - The Phase I/IIa clinical trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, with preliminary efficacy indicators focusing on reducing alcohol cravings and consumption [2][4]. - The trial is a multinational, multicenter study that will explore early signals of efficacy, including reductions in alcohol consumption and cravings, which could facilitate further development of this therapy [4]. Group 2: Company Strategy and Goals - The activation of new clinical sites and participant enrollment is seen as a step closer to validating CMND-100's potential to transform the treatment landscape for AUD, reflecting the scientific community's interest in the company's approach [3][5]. - Clearmind's primary objective is to research and develop psychedelic-based compounds and commercialize them as regulated medicines, foods, or supplements, addressing widespread and underserved health problems [5]. Group 3: Intellectual Property - The company currently holds an intellectual portfolio consisting of nineteen patent families, including 31 granted patents, and plans to seek additional patents for its compounds as warranted [6].

Core Viewpoint - Clearmind Medicine Inc. has received Institutional Review Board (IRB) approval for its Phase 1/2a clinical trial of CMND-100, a MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][3][4] Group 1: Clinical Trial Details - The trial will take place at Tel Aviv Sourasky Medical Center (TASMC) and includes participation from other prestigious institutions such as Yale School of Medicine and Johns Hopkins University [2] - The trial aims to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also evaluating its preliminary efficacy in reducing alcohol cravings and consumption in patients with AUD [4] Group 2: Company Background and Objectives - Clearmind is focused on the discovery and development of novel psychedelic-derived therapeutics to address under-treated health issues, including AUD [5] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [6] Group 3: Market Context and Impact - AUD is a significant global health issue, accounting for 4.7% of all deaths worldwide, highlighting the urgent need for effective treatments [4] - The company aims to provide a transformative treatment for individuals affected by AUD, which impacts millions of lives globally [4]

Core Viewpoint - Clearmind Medicine Inc. has achieved a significant milestone by dosing the first participant with its proprietary drug candidate CMND-100 in a Phase I/IIa clinical trial aimed at treating Alcohol Use Disorder (AUD) [1][3]. Group 1: Clinical Trial Details - The Phase I/IIa trial is being conducted at prestigious clinical sites, including Yale School of Medicine, Johns Hopkins University, and medical centers in Israel [2]. - The trial's objectives include evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, as well as assessing its preliminary efficacy in reducing alcohol cravings and consumption [2][3]. - This trial represents the first time Clearmind's neuroplastogen compound has been administered to humans in a controlled clinical setting [3]. Group 2: Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health issues, particularly AUD [4]. - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5].

Core Insights - Clearmind Medicine Inc. has added Hadassah-University Medical Center in Jerusalem as a new clinical site for its Phase I/IIa trial of CMND-100, a drug candidate for Alcohol Use Disorder (AUD) [1][2] - The trial aims to evaluate the safety, tolerability, and pharmacokinetics of CMND-100, while also assessing its potential to reduce alcohol cravings and consumption [3] - Alcohol Use Disorder affects over 280 million people globally, indicating a significant unmet medical need and a potential multibillion-dollar market opportunity [4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address major health issues, including AUD [6] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [7] Clinical Trial Details - The inclusion of Hadassah-University Medical Center is expected to enhance patient recruitment, accelerate data collection, and increase the statistical power of the study [3][5] - Other participating institutions include Yale School of Medicine, Johns Hopkins University, and Tel Aviv Sourasky Medical Center [2]

Core Insights - Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a proprietary MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD), which affects hundreds of millions globally [1][2] - The trial's primary focus is on evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, with preliminary efficacy assessments to determine its potential in reducing alcohol cravings and consumption [2] Company Overview - Clearmind is a clinical-stage biotech company dedicated to developing novel psychedelic-derived therapeutics to address significant health issues, including AUD [4] - The company has a robust intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5] Market Potential - The substance use disorder treatment market in the U.S. was valued at $35.1 billion in 2021 and is projected to grow to $60.2 billion by 2029, indicating a significant opportunity for innovative treatments like CMND-100 [3]

Core Insights - Clearmind Medicine Inc. is advancing its mission to develop psychedelic-derived therapeutics by engaging a prominent government and political affairs consulting firm to navigate regulatory landscapes and promote acceptance among U.S. policymakers [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on discovering and developing novel psychedelic-derived therapeutics aimed at addressing major under-treated health issues, including alcohol use disorder [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property as opportunities arise [5] Industry Context - The pharmaceutical industry is increasingly recognizing the potential of psychedelics to treat conditions such as Post-Traumatic Stress Disorder (PTSD) and other mental health disorders, necessitating informed regulatory frameworks to facilitate the integration of these therapies into mainstream healthcare [2][3] - Clearmind's lead candidate, CMND-100, is currently undergoing Phase I/IIa clinical trials for alcohol use disorder at prestigious institutions, including Yale School of Medicine and Johns Hopkins University [3]

Core Viewpoint - Clearmind Medicine Inc. has expanded its Phase I/IIa clinical trial for CMND-100, a drug candidate for Alcohol Use Disorder (AUD), by adding Tel Aviv Sourasky Medical Center as a clinical site, following the enrollment of the first patient [1][3]. Group 1: Clinical Trial Expansion - The addition of Tel Aviv Sourasky Medical Center, led by Dr. David Zeltser, enhances the trial's capacity to evaluate CMND-100's safety, tolerability, and pharmacokinetic profile [2]. - Other prestigious institutions involved in the trial include Yale School of Medicine and Johns Hopkins University, indicating a strong clinical network [2][3]. Group 2: Company Objectives and Focus - Clearmind is focused on developing novel psychedelic-derived therapeutics to address major under-treated health issues, particularly AUD, which affects millions and is responsible for 2.6 million deaths annually [3][4]. - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4]. Group 3: Intellectual Property - Clearmind's intellectual portfolio includes nineteen patent families with 31 granted patents, and the company plans to seek additional patents to strengthen its position [5].

Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three and Six Months Ended April 30, 2025 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) | | April 30, | | October 31, | | --- | --- | --- | --- | | | 2025 | | 2024 | | Assets | | | | | Current assets | | | | | Cash and cash equivalents | $ 4,472,520 | | $ 6,573,813 | | Other ...

Core Insights - Clearmind Medicine Inc. has engaged a leading government and political affairs consulting firm to advance its mission of developing psychedelic-based therapeutics [1][2] - The company aims to navigate complex regulatory landscapes and promote acceptance of psychedelic therapies among U.S. policymakers [2][3] - Clearmind's lead candidate, CMND-100, is currently in Phase I/IIa clinical trials for alcohol use disorder (AUD) at prestigious institutions [3] Company Overview - Clearmind is a clinical-stage biotech company focused on discovering and developing psychedelic-derived therapeutics to address under-treated health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5] Industry Context - The pharmaceutical industry is increasingly recognizing the potential of psychedelics to treat mental health disorders such as PTSD [2] - The partnership with the consulting firm aims to educate policymakers on the therapeutic potential of psychedelics and support the development of balanced regulations [3]